Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’

Phase 1negativeBI 3031185Negative

AI Analysis

Summary

Boehringer Ingelheim suspended an early-stage study of pill candidate BI 3031185 following a safety event. The drug had previously completed at least two Phase 1 studies earlier this year.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Early study suspended due to safety event

Importance:6/10

Sentiment:

-0.80

safetytrial suspensionearly stageadverse event

Read the original article

Published by BioSpace on August 24, 2026 11:47 AM

Read Original